A prominent doctor and healthcare expert says three key factors will drive continued future growth in personalized medicine and these elements spell opportunity for Rainbow Coral Corp.(OTCQB:RBCC) as it ramps up its efforts in this increasingly important field.

According to Dr. David Delaney, a physician at Boston’s Beth Israel Deaconess Medical Center and a former faculty member of Harvard Medical School, “one-size-fits-all” medicine no longer works. Instead, Delaney says personalized medicine – treating a patient based on their unique genomes, characteristics and data – will become the norm.

The reasons for this, Delaney says, are: Patients will start to act more as consumers, a shift to value-based care and advances in computing technology that will make it easier to process the large amount of data necessary in personalized medicine.

RBCC CEO Kimberly Palmer says Delaney’s analysis is spot-on and validates the company’s aggressive strategy regarding personalized medicine. “This type of medicine is the wave of the future. Doctors and patients are rapidly beginning to see the power and the value of personalized medicine. It has the capability of generating solid returns on investment and we intend to make it a major portion of our business moving forward.”

One major forecast predicts personalized medicine will grow to a nearly $2.5 billion industry by 2022, a nearly 150 percent increase over its current size of $1 billion.

Through its biotech subsidiary, Rainbow Biosciences, RBCC seeks to develop and market new medical technology to compete alongside companies such as Biogen Idec Inc. (BIIB), Abbott Laboratories (ABT) and Amgen Inc. (AMGN).

For more information on RBCC’s initiatives, please visit www.rainbowbiosciences.com.


Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.


Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.